Pfizer Inc vs Standard Lithium Ltd — how do they compare? Pfizer Inc trades at $27.85 (market cap $158.39B), while Standard Lithium Ltd trades at $2.37 (market cap $589.88M). The key difference: Pfizer Inc is far larger — about 268.5× Standard Lithium Ltd's market cap, and Pfizer Inc pays a 6.19% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| PFE | SLI | |
|---|---|---|
Market Cap | $158.39B | $589.88M |
Volume | 29,869,932 | — |
Sector | Health | Basic Materials |
52-Week High | $29.02 | $5.65 |
52-Week Low | $23.60 | $1.93 |
Enterprise Value | $209.89B | $452.79M |
Dividend Yield | 6.19% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Standard Lithium (SLI) trades at $2.40, down 0.83% today, with a bullish technical signal despite negative profitability metrics. The company shows progress with recent DOE clearance and key customer agreements, including LG Energy Solution, while maintaining 100% analyst buy ratings. Cash flow remains positive primarily from financing activities, though operational cash flow is negative as the company invests heavily in lithium project development.
The outlook hinges on successful project execution and Final Investment Decision for the Arkansas lithium project, which could unlock $250 million in government funding. Key risks include execution delays and negative profitability, but strong institutional interest and supportive government policies for critical minerals provide upside potential for patient investors.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →